Recently, the Federal Commission for Protection against Health Risks (COFEPRIS) approved the use of tirzepatida in Mexico, an innovative medicine to treat type 2 diabetes that has also shown promising results in weight loss.This advance represents a new option in the pharmaceutical career that competes with other drugs such as Ozempic.

What is the tirzepatida and how does it work?

Tirzepatida is a subcutaneous injection medication that is used together with diet and exercise to reduce blood sugar levels in patients with type 2 diabetes. It is also prescribed for weight loss in people with obesity or overweight that can present conditions such asHypertension, sleep apnea, cardiovascular diseases or high cholesterol.

It belongs to a class of medications called agonists of the GIP and LPG-1 receiver, who work as follows:

  • They increase insulin production.
  • They reduce glucagon levels, a hormone that controls glucose production in the liver.
  • They slow down gastric emptying, reducing appetite.
  • They regulate energy balance and reduce fat accumulation.

A study led by Yale University and published in the New England Journal of Medicine showed impressive results in more than 2,000 adults treated with Tirzepatida.Participants achieved weight reductions between 19.5% and 20.9% after receiving the medicine.

In addition, treatment not only helps weight loss, but also improves other health markers, such as blood sugar control, blood pressure and lipid levels.

Like any medication, the tirzepatida is not exempt from possible side effects.Among the most common, reported by the FDA, are:

  • Nausea, diarrhea, vomiting and constipation.
  • Abdominal pain and gastroesophageal reflux.
  • Fatigue and allergic reactions.
  • Reactions at the injection place.
  • In rare cases, there could be a risk associated with thyroid C cell tumors in animals, although it has not been proven in humans.

Important contraindications:

  • It should not be used in patients with personal or family history of medullary thyroid cancer.
  • Nor in people with multiple endocrine neoplasia syndrome type 2.

While the tirzepatida represents a promising solution for both diabetes type 2 and for weight control, it is essential to have a specialist's guide before starting this treatment.The doctor will determine whether it is appropriate according to the patient's medical history and the possible contraindications.

The arrival of the Tirzepatida in Mexico opens new doors to improve the quality of life of those who live with type 2 diabetes or face challenges related to weight.However, as always, the base of treatment remains a balanced diet, regular exercise and a comprehensive health approach.

Have you heard of this medicine or do you have experience with similar treatments?

Greetings,